CN101143863A - Resolution for 5-methyltetrahydrofolic acid and salifying method thereof - Google Patents
Resolution for 5-methyltetrahydrofolic acid and salifying method thereof Download PDFInfo
- Publication number
- CN101143863A CN101143863A CNA2006100415414A CN200610041541A CN101143863A CN 101143863 A CN101143863 A CN 101143863A CN A2006100415414 A CNA2006100415414 A CN A2006100415414A CN 200610041541 A CN200610041541 A CN 200610041541A CN 101143863 A CN101143863 A CN 101143863A
- Authority
- CN
- China
- Prior art keywords
- mthf
- methyl tetrahydrofolate
- preparation
- ben yian
- resolution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention brings forward a preparation method, which utilizes organic alkali Alpha-phenylethylamine to obtain (6S)-5-methyltetrahydrofolate by splitting racemate (6R, S)-5-methyltetrahydrofolate, and utilizes the hydroxide of alkaline earth, particularly calcium hydroxide, to generate (6S)-5-methyltetrahydrofolate calcium salt.
Description
Invention field
The present invention relates to organic chemistry filed, in particular to organic drug (6S)-5-methyl tetrahydrofolate from (6R, S)-fractionation and the salifiable method of 5-methyl tetrahydrofolate.
Background technology
(6S)-and the chemical name of 5-methyl tetrahydrofolate is N-(5-methyl)-6 (S)-5,6,7,8, and-tetrahydro pteroyl base-L-L-glutamic acid is called for short (6S)-5-MTHF, and structural formula is as follows:
(6S)-the 5-methyl tetrahydrofolate is the principal mode of tissue and blood folic acid.Participate in multiple important biochemical reaction in the body (as the biosynthesizing of purine and thymus pyrimidine etc.).Naturally occurring 5-MTHF only is the S type, and synthetic R type non-activity on biological chemistry excretes by kidney.(6S)-5-MTHF do not need can directly be utilized through loaded down with trivial details enzymatic metabolism step in human body.(Zhang Yue etc., meticulous and chemical, 13, (22), 13,2005).
More first, (6S)-5-MTHF has the vital role of two aspects as medicine: in the oncology treatment, unites with methotrexate (Methotrexate) and 5 FU 5 fluorouracil (5-Fluorouracil) and treats tumour; The anaemia that treatment is caused by folic acid.Nearest studies show that: (6S)-and 5-MTHF uniquely in the folic acid class medicine can see through hemato encephalic barrier, have the medicine of the effect of control Alzheimer (senile dementia).Synthetic (6S)-5-MTHF is main medicament active composition and foodstuff additive, and prevention fetal nerve defective tube is arranged, arteriosclerosis, effects such as treatment megaloblastic anemia.
Generally speaking, extract from human body or animal tissues and blood, separation and purifying (6S)-5-MTHF are difficult, and the cost costliness.And use synthetic method is to be carried out hydrogenation and methylation reaction and prepared (6R, S) racemic modification (Federico.G etal, GB1572138,1977 by folic acid; U.S5,124,452,1978).Once the someone thought and split into corresponding enantiomorph 6R-acid or 6S-acid is impossible with chemical process.(Clinical?Science?andMolecular?Medicine45,625-631，1973)
And Klaus.S etc. proposed with organic bases N-ethyl-2-aminomethylpentazaneand or its enantiomorph be resolving agent be feature from racemic modification (6R, S)-method (U.S5 of 5-methyl tetrahydrofolate preparation (6S)-5-methyl tetrahydrofolate, 457,202,1992), for split (6R, S)-5-MTHF started precedent, but since N-ethyl-2-aminomethyl pyrroles especially the enantiomorph market value of (+) or (-) is more expensive, limited its application; What the document that has was used when generating calcium salt is calcium chloride (Fedrico G, etal, U.S5,124,452,1992), finally easy residual a large amount of chlorion and cause the chlorion limit examine that does not meet medicine or foodstuff additive in product (6S)-5-MTHF-Ca.
Summary of the invention
For fear of the existing (6R that splits, S)-defective and the weak point that exist in 5-MTHF and the salifiable technological process, the present invention proposes the organic bases α-Ben Yian that is easy to get with market and its enantiomorph and be resolving agent and be feature from racemic modification (6R, S)-the 5-methyl tetrahydrofolate splits the method for preparation (6S)-5-methyl tetrahydrofolate, and then with alkaline earth metal hydroxides or oxide compound, for example calcium hydroxide or magnesium hydroxide or zinc oxide are made (6S)-5-methyl tetrahydrofolate calcium salt or magnesium salts or zinc salt.
Defective and weak point at above-mentioned existing document (6S)-5-MTHF and its salt preparation method, we have found that can split (a 6R, S)-organic bases and the optical antipode thereof of 5-MTHF, and then find with the oxyhydroxide of alkaline-earth metal or the oxide compound method of calcium hydroxide or magnesium hydroxide or the salifiable preparation of zinc oxide (6S)-5-MTHF salt for example.
In view of (6S)-5-MTHF-Ca is difficult for crystalline deposit in water, the present invention further uses 95% ethanol, also can make it precipitated crystal with dehydrated alcohol, preferred 95% ethanol.
The present invention relates to the technological process of preparation (6S)-5-methyl tetrahydrofolate, split from racemic modification by the application organic bases and obtain product, wherein organic bases is the enantiomorph of α-Ben Yian or (+) or (-); α-Ben Yian is water-soluble, be heated to 20-80 ℃, stir down, repeatedly add on a small quantity (6R, S)-the 5-MTHF aqeous suspension, stir and progressively make it to dissolve complete salify, salt is cooled to 20 ℃, the salt crystallization that 6S-acid generates is filtered and separated; The salt suspension that 6S-acid is generated adds sodium hydroxide solution in water again, makes it into the sodium salt dissolving; Under 20-60 ℃, add calcium hydroxide again, repeatedly stirring adds on a small quantity, till dissolving; Add 95% ethanol then, make to produce precipitation, promptly be prepared into (6S)-5-methyl tetrahydrofolate calcium salt.
Above-mentioned already mentioned α-Ben Yian can be a racemic modification, also can be single optical isomer, and (-)-α-Ben Yian is first-selected.
Racemic modification (6R, S)-5-MTHF provides Calciumlevofolinate (Calcium Falinate) through neutralization reduction and prepare by the Su Rui of Suzhou City, Jiangsu Province medication chemistry company limited; α-Ben Yian and enantiomorph are to reach chemical industry company limited by Changzhou, Jiangsu Province Ke Run to provide.
The invention will be further described below by embodiment.It should be understood that the described preparation method of the embodiment of the invention is only used for illustrating the present invention, rather than limitation of the present invention, down preparation method's of the present invention simple modifications is all belonged to the scope of protection of present invention in advance in design of the present invention.Except as otherwise noted, the percentage ratio among the present invention is weight percentage.
Embodiment one,
In the 1000ml three-necked bottle, add 56.0g (0.4mol) (±)-α-Ben Yian and 300ml water, add again contain 107.1g (0.2mol) (6R, S)-the 300ml aqueous solution of 5-MTHF, stir, reacting by heating to 80 ℃ is cooled to 60 ℃, removes by filter sl. sol. 6R-hydrochlorate.Filtrate is added activated carbon decolorizing, filter, be cooled to 20 ℃, have crystallization to produce, vacuum filtration gets 6S-hydrochlorate crystallization 42.8g, yield 36.9%, [α]
20 D:+22.1 ° (C=1, ethanol).
Obtain to such an extent that the 6S-hydrochlorate is suspended in the 200ml water with above-mentioned, gradation adds 5.9g (0.08mol) calcium hydroxide powder, and stir on the limit, and the limit is heated to 40 ℃, to all dissolvings; Add 95% ethanol while cooling off, progressively adularescent or faint yellow precipitation produce, and filtration drying gets (6S)-5-MTHFCa5H
2O39.1g, primary crystallization yield 95.1%, [α]
20 D:+34.5 ° of (C=1, H
2O) optical purity 〉=98.5%.
Embodiment two,
In the three-necked bottle of 1000ml, add 28.0g (0.2mol) (-)-α-Ben Yian and water 150ml, add again contain 107.1g (0.2mol) (6R, S)-the 300ml aqueous solution of 5-MTHF, be heated to 75 ℃, be cooled to 55 ℃, remove by filter undissolved 6R-hydrochlorate, mother liquor is added gac, filter, be cooled to 18-20 ℃, have crystallization to produce, vacuum filtration, get crystallization 6S-hydrochlorate 47.4g, yield 40.8%, [α]
20 D:+22.5 ° (C=1, ethanol).
The above-mentioned 6S-hydrochlorate that obtains is suspended in water, add 10% sodium hydroxide solution, making pH value is 8-9, makes temperature be no more than 30 ℃, gradation adds 7.4g (0.1mol) calcium hydroxide powder then, warm while stirring, temperature is no more than 40 ℃, should all dissolve, stir and add 95% ethanol down, adularescent precipitation or faint yellow precipitation produce, and filtration drying gets 46.4g (6S)-5-MTHFCa5H
2O, primary crystallization yield 96.2%, [α]
20 D:+35.1 ° of (C=1, H
2O) optical purity 〉=99.0%.
Embodiment three,
In the three-necked bottle of 1000ml, add 28.0g (0.2mol) (+)-α-Ben Yian and water 150ml, add again contain 107.1g (0.2mol) (6R, S)-the 300ml aqueous solution of 5-MTHF, operation is with embodiment one, get the 44.496S-hydrochlorate, yield 38.2%, [α]
20 D:+21.8 ° (C=1, ethanol).
The above-mentioned 6S-hydrochlorate that obtains is suspended in the 200ml water, join in the aqueous sodium carbonate, the pH value that makes solution is 7.5-8.5, and gradation adds 0.1mol calcium hydroxide powder then, warm while stirring, temperature is no more than 40 ℃, should all dissolve, and stirs down, add 95% ethanol, adularescent precipitation or faint yellow precipitation produce, and filtration drying gets 45.2g (6S)-5-MTHFCa5H
2O, primary crystallization yield 96.1%, [α]
20 D:+34.5 ° of (C=1, H
2O) optical purity 〉=99.0%.
Claims (4)
- One kind use the organic bases resolution of racemates (6R, S)-5-methyl tetrahydrofolate preparation (6S)-5-methyl tetrahydrofolate, again with the method for alkaline earth metal hydroxides or oxide compound salify preparation (6S)-5-methyl tetrahydrofolate calcium.
- 2. according to the process of claim 1 wherein that organic bases is (±)-α-Ben Yian, (+)-α-Ben Yian or (-)-α-Ben Yian.
- 3. according to the process of claim 1 wherein that the oxyhydroxide or the oxide compound of alkaline-earth metal are calcium hydroxide or magnesium hydroxide or zinc oxide.
- 4. be dissolved in water according to the process of claim 1 wherein earlier in the salifiable process of (6S)-5-methyl tetrahydrofolate, the back is with 95% ethanol or the sedimentary method of dehydrated alcohol.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100415414A CN101143863B (en) | 2006-09-13 | 2006-09-13 | Resolution for 5-methyltetrahydrofolic acid and salifying method thereof |
| PCT/CN2006/002615 WO2008031284A1 (en) | 2006-09-13 | 2006-10-08 | A process for resolution of 5-methyltetrahydrofolic acid and its salification |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100415414A CN101143863B (en) | 2006-09-13 | 2006-09-13 | Resolution for 5-methyltetrahydrofolic acid and salifying method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101143863A true CN101143863A (en) | 2008-03-19 |
| CN101143863B CN101143863B (en) | 2010-08-11 |
Family
ID=39183367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100415414A Expired - Fee Related CN101143863B (en) | 2006-09-13 | 2006-09-13 | Resolution for 5-methyltetrahydrofolic acid and salifying method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101143863B (en) |
| WO (1) | WO2008031284A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102516247A (en) * | 2010-12-15 | 2012-06-27 | 连云港金康医药科技有限公司 | A-type calcium L-5-methyltetrahydrofolate polymorphism and preparation method thereof |
| CN102584826A (en) * | 2012-01-20 | 2012-07-18 | 连云港金康医药科技有限公司 | (6S)-5-methyltetrahydrofolate crystal form and preparation method thereof |
| CN102702200A (en) * | 2012-04-25 | 2012-10-03 | 连云港金康和信药业有限公司 | (6RS)-5-methyl tetrahydrofolate calcium salt crystal form and preparation process thereof |
| CN103664945A (en) * | 2012-09-07 | 2014-03-26 | 南京莱因医药科技有限公司 | Preparation method of L-5-methyl tetrahydrofolate amino acid salt |
| CN104557937A (en) * | 2012-01-20 | 2015-04-29 | 连云港金康医药科技有限公司 | (6S)-5-methyl tetrahydrofolate crystal form and preparation method thereof |
| JP2015513360A (en) * | 2012-04-13 | 2015-05-11 | ▲連雲▼港金康和信▲薬業▼有限公司Ｌｉａｎｙｕｎｇａｎｇ Ｊｉｎｋａｎｇ Ｈｅｘｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Compound JK12A and its production |
| CN109164182A (en) * | 2018-09-19 | 2019-01-08 | 江苏红豆杉药业有限公司 | A kind of analyzing detecting method of pair of L- tetrahydrofolic acid tosilate (6S) optical purity |
| CN111620777A (en) * | 2020-06-10 | 2020-09-04 | 成都蓝蜻蜓生物技术有限公司 | Resolution method of (S) -1,2,3, 4-tetrahydro-1-naphthoic acid |
| CN111635405A (en) * | 2020-07-02 | 2020-09-08 | 无锡紫杉药业有限公司 | Production process of calcium tetrahydrofolate preparation |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2541314T3 (en) * | 2008-02-20 | 2015-07-17 | Gnosis S.P.A. | Procedure for diastereoisomeric resolution of 5-methyltetrahydrofolic acid |
| CN103214487A (en) * | 2013-04-12 | 2013-07-24 | 张家港威胜生物医药有限公司 | Synthesis of important medical chemical raw material (6S)-5-methyl tetrahydrofolate |
| WO2015193778A1 (en) * | 2014-06-16 | 2015-12-23 | Mylan Laboratories Ltd. | Crystalline form of levomefolate calcium |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4136921A1 (en) * | 1991-11-11 | 1993-05-13 | Knoll Ag | METHOD FOR SEPARATING 5-METHYL-TETRAHYDROFOLIC ACID |
-
2006
- 2006-09-13 CN CN2006100415414A patent/CN101143863B/en not_active Expired - Fee Related
- 2006-10-08 WO PCT/CN2006/002615 patent/WO2008031284A1/en not_active Ceased
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102516247A (en) * | 2010-12-15 | 2012-06-27 | 连云港金康医药科技有限公司 | A-type calcium L-5-methyltetrahydrofolate polymorphism and preparation method thereof |
| CN104557937B (en) * | 2012-01-20 | 2017-03-08 | 连云港金康和信药业有限公司 | (6S) 5 methyl tetrahydrofolate salt crystal formations and preparation method thereof |
| CN102584826A (en) * | 2012-01-20 | 2012-07-18 | 连云港金康医药科技有限公司 | (6S)-5-methyltetrahydrofolate crystal form and preparation method thereof |
| CN102584826B (en) * | 2012-01-20 | 2015-04-29 | 连云港金康医药科技有限公司 | (6S)-5-methyltetrahydrofolate crystal form and preparation method thereof |
| CN104557937A (en) * | 2012-01-20 | 2015-04-29 | 连云港金康医药科技有限公司 | (6S)-5-methyl tetrahydrofolate crystal form and preparation method thereof |
| JP2015513360A (en) * | 2012-04-13 | 2015-05-11 | ▲連雲▼港金康和信▲薬業▼有限公司Ｌｉａｎｙｕｎｇａｎｇ Ｊｉｎｋａｎｇ Ｈｅｘｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Compound JK12A and its production |
| US9090623B2 (en) | 2012-04-13 | 2015-07-28 | Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | Compound JK12A and preparation thereof |
| CN102702200A (en) * | 2012-04-25 | 2012-10-03 | 连云港金康和信药业有限公司 | (6RS)-5-methyl tetrahydrofolate calcium salt crystal form and preparation process thereof |
| CN102702200B (en) * | 2012-04-25 | 2014-11-12 | 连云港金康和信药业有限公司 | (6RS)-5-methyl tetrahydrofolate calcium salt crystal form and preparation process thereof |
| CN103664945A (en) * | 2012-09-07 | 2014-03-26 | 南京莱因医药科技有限公司 | Preparation method of L-5-methyl tetrahydrofolate amino acid salt |
| CN103664945B (en) * | 2012-09-07 | 2016-01-20 | 南京莱因医药科技有限公司 | The preparation method of L-5-methyl tetrahydrofolate amino acid salts |
| CN109164182A (en) * | 2018-09-19 | 2019-01-08 | 江苏红豆杉药业有限公司 | A kind of analyzing detecting method of pair of L- tetrahydrofolic acid tosilate (6S) optical purity |
| CN109164182B (en) * | 2018-09-19 | 2021-06-11 | 无锡紫杉药业有限公司 | Method for analyzing and detecting optical purity of L-tetrahydrofolic acid p-toluenesulfonate (6S) |
| CN111620777A (en) * | 2020-06-10 | 2020-09-04 | 成都蓝蜻蜓生物技术有限公司 | Resolution method of (S) -1,2,3, 4-tetrahydro-1-naphthoic acid |
| CN111635405A (en) * | 2020-07-02 | 2020-09-08 | 无锡紫杉药业有限公司 | Production process of calcium tetrahydrofolate preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008031284A1 (en) | 2008-03-20 |
| CN101143863B (en) | 2010-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103119044B (en) | Calcium salt of pyrroloquinoline quinone | |
| CN104744462B (en) | The sodium salt crystal of pyrro-quinoline quinone (PQQ), its preparation method, functional food and medicine | |
| CN101143863B (en) | Resolution for 5-methyltetrahydrofolic acid and salifying method thereof | |
| JP6160621B2 (en) | Pyrroloquinoline quinone tetraalkali salt and crystal thereof, production method thereof, and composition | |
| CN103664945B (en) | The preparation method of L-5-methyl tetrahydrofolate amino acid salts | |
| JP5979376B2 (en) | Highly soluble pyrroloquinoline quinone salt and method for producing the same | |
| TW200838513A (en) | Raf kinase inhibitors containing a zinc binding moiety | |
| JP2017526699A (en) | Composition of (6S) -5-methyltetrahydrofolic acid or its salt and its preparation and application | |
| JP6166736B2 (en) | Crystalline form of (6S) -5-methyltetrahydrofolate and method for producing the same | |
| AU2008255518A1 (en) | Process for preparing the stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid | |
| JP5636671B2 (en) | Method for producing pyrroloquinoline quinone Li salt | |
| CA2984961C (en) | Sodium salt of uric acid transporter inhibitor and crystalline form thereof | |
| CN104364248A (en) | Flumatinib mesylate crystal form and preparation method and use thereof | |
| CN100484526C (en) | Compounding method of cefpirome sulfate raw material and uses thereof | |
| CN114073704A (en) | Use of fluoro-heterocyclic derivatives having macrocyclic structure | |
| CN103450202B (en) | Method for reacting L-5-methyltetrahydrofolic acid with organic base to form salt | |
| US10100055B2 (en) | Imidazopyrroloquinoline salt, method for producing the same, medicament, cosmetic, and food | |
| JP6428527B2 (en) | Method for producing pyrroloquinoline quinone crystals | |
| CN103159673A (en) | Refining method for preparing gimeracil | |
| CN107207494A (en) | The high acetone addition PQQ salt of dissolubility | |
| RU2429224C1 (en) | Mixed anhydride of dichloroacetic and aminoacetic acid and production method thereof | |
| RU2186068C2 (en) | Method of purification of cis-dichloroamminiso-propylaminplatinum (ii) | |
| CN101077862B (en) | D-glucose-L-amino acid, preparation method and application thereof | |
| CN104530051A (en) | Stable (6R, S)-5-methyl tetrahydrofolic acid crystal form and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100811 Termination date: 20110913 |